Journal profile · Pharmacology & Pharmacy
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
ISSN 0011-393X · eISSN 1879-0313 · Elsevier Inc. · UNITED STATES · Bimonthly · Founded 1959
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3 (journal website); fully open access; APC about USD 2,740; median 122 days to acceptance (78 articles, last 24 months); community-reported acceptance: about 75%; 41 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is published by Elsevier Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Blood Pressure and Hypertension Studies, Lipoproteins and Cardiovascular Health and Antibiotics Pharmacokinetics and Efficacy, together about 23.9% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Current Therapeutic Research (CTR) is a multidisciplinary, peer-reviewed Open Access journal focused on publication of the manuscripts related to the discovery, development, and use of therapeutics and interventions across all therapeutic areas and all therapeutic modalities. CTR has a long-standing history of publishing high-quality, rigorous, and ethically sound original research, whether the results are positive, confirmatory, or negative, with the goal of improving healthcare.CTR promotes collaborative and interdisciplinary work with objectivity, criticism, creativity, innovation, and respect for cultural and professional diversity. Indexing and Database CoverageArticles published in Current Therapeutic Research are indexed by all major biomedical abstracting databases (e.g., PubMed/Medline, Clarivate, Scopus).The target audienceThe journal is read by scientists and healthcare professionals in various research, academic, and clinical practice settings regardless of their discipline or specialty.The journal publishes in depth review articles, meta-analyses, commentaries, brief reports, case reports, research letters, and letters to the editor.Topics of interest for CTR are related to:Experimental medicine and therapeutics, translational medicine, clinical use of medicines and safe medicine use.New or existing drug pharmacology, pharmacotherapy, pharmacovigilance, pharmacoepidemiology, pharmacoeconomic, personalized medicine and ethnopharmacology.Clinical trials, drug disposition and effects, pharmaceutical medicine, pharmacodynamics, pharmacokinetics and toxicology.Pharmacometrics: PK/PD modeling, PBPK modeling, clinical trial modeling and simulation.Pediatric clinical trials and pediatric and maternal-fetal pharmacology and toxicology.Evidence based -complementary medicine and therapies including natural or herbal medicines that complement or replace conventional therapies covering mechanisms of action, efficacy, safety, costs, patterns of use and implementation. CTR will not accept studies on traditional medicines (e.g. traditional Chinese medicines, Kampo medicines, Japanese traditional medicines) or crude natural products, even if used as complementary therapy.Studies relating to nutritional therapy, diagnostics and diagnosis, public health, quality of life, patient care, management, and education are also encouraged.Interventions focused on all aspects of clinical therapy, including non-pharmacological ones.Research may involve preclinical and clinical studies and utilize both in vitro and in vivo approaches.Current Therapeutic Research promotes inclusion and diversity by considering submissions from all over the world, whether they relate to an international or a country-specific audience (e.g., a specific patient population).
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Katarina IlicPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named United States 16, Australia 4, Russia 4, Germany 2, Spain 2 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Blood Pressure and Hypertension StudiesMedicine12.2%
- Lipoproteins and Cardiovascular HealthMedicine6.2%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.5%
- Pneumonia and Respiratory InfectionsMedicine4.8%
- Asthma and respiratory diseasesMedicine4.5%
- Diabetes Treatment and ManagementMedicine4.2%
- Pharmacology and Obesity TreatmentMedicine4.2%
- Hormonal Regulation and HypertensionMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPublisher website
Other: Clarivate
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 3.7LetPub ·
- CiteScore (publisher)
- 3.7Publisher website ·
- SJR 2026-06
- 0.61LetPub ·
- SNIP 2026-06
- 0.9LetPub ·
- h-index
- 34LetPub ·
- h-index
- 59OpenAlex ·
- i10-index
- 678OpenAlex ·
- 2-year mean citedness
- 4.12OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 44LetPub ·
Articles by year OpenAlex count · 2,617 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 28 | 28 | 12 |
| 2025 | 41 | 41 | 87 |
| 2024 | 44 | 44 | 366 |
| 2023 | 37 | 37 | 237 |
| 2022 | 29 | 29 | 277 |
| 2021 | 38 | 38 | 306 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
122 daysMedian, submission to acceptance · P25–P75 82 days – 167 days
- Acceptance to online
- median 4 days (78 articles)
- Submission to online
- median 130 days
- Sample
- 78 articles with submission and acceptance dates (82 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 47 daysPublisher website ·
- Submission to acceptance
- 142 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Submission to publication (journal-reported)
- about 26 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,740 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,690 / EUR 2,520 / GBP 2,150 / JPY 333,640 | — | — | |
| LetPub | USD 2,000 | Yes | — | |
| Publisher website | USD 3,100 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 6,000 words
- Reference style
- Vancouver
- Suggested reviewers
- Optional
- Highlights
- Optional
Article types accepted9
- commentariesThese papers address an important issue in clinical medicine, health policy, or medical research in a thorough, well-referenced, systematic, or evidence-based m…Length not stated
- editorialPublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- meta-analysisPublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- original researchPublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- original research articlePublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- reviewPublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- review articlePublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
- review articles and meta-analysesComprehensive evidence-based reviews, systematic reviews, and meta-analyses of the literature are welcomed.Length not stated
- systematic reviewPublished articles cover the entire spectrum of therapeutics, including preclinical, clinical, postmarketing, outcomes, pharmacoeconomics, alternative medicine,…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1959
- ISSN
- 0011-393X
- Electronic ISSN
- 1879-0313
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
What CAS zone is CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL in?
In the 2025 upgraded edition of the CAS Journal Ranking, CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL?
The journal's website gives an impact factor of 3; this is the journal's own figure, as LetPub lists none for it; CiteScore 3.7, h-index 59.
How long does peer review take at CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL?
Based on the dates recorded on 78 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 82–167 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 6,000 words; Reference style: Vancouver; Suggested reviewers: Optional; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL based?
Of the 33 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are United States (16), Australia (4) and Russia (4). Counted from the institutions listed on the board page; for reference only.
Which databases index CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL?
According to LetPub and DOAJ records, CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is indexed in ESCI, Scopus and DOAJ. The journal's website also lists MEDLINE; that list has not been checked against each database.
Is CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL open access, and what is the APC?
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a fully open-access journal. APC about USD 2,740.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .